Investigators evaluated the effectiveness of an immunotherapy in combination with standard radiation therapy for patients with intermediate-high risk localized prostate cancer.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...